Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: Results from the actionable genome consortium

123Citations
Citations of this article
236Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Noninvasive genotyping using plasma cell-free DNA (cfDNA) has the potential to obviate the need for some invasive biopsies in cancer patients while also elucidating disease heterogeneity. We sought to develop an ultra-deep plasma next-generation sequencing (NGS) assay for patients with non-small-cell lung cancers (NSCLC) that could detect targetable oncogenic drivers and resistance mutations in patients where tissue biopsy failed to identify an actionable alteration. Patients and methods: Plasma was prospectively collected from patients with advanced, progressive NSCLC. We carried out ultra-deep NGS using cfDNA extracted from plasma and matched white blood cells using a hybrid capture panel covering 37 lung cancer-related genes sequenced to 50 000× raw target coverage filtering somatic mutations attributable to clonal hematopoiesis. Clinical sensitivity and specificity for plasma detection of known oncogenic drivers were calculated and compared with tissue genotyping results. Orthogonal ddPCR validation was carried out in a subset of cases. Results: In 127 assessable patients, plasma NGS detected driver mutations with variant allele fractions ranging from 0.14% to 52%. Plasma ddPCR for EGFR or KRAS mutations revealed findings nearly identical to those of plasma NGS in 21 of 22 patients, with high concordance of variant allele fraction (r = 0.98). Blinded to tissue genotype, plasma NGS sensitivity for de novo plasma detection of known oncogenic drivers was 75% (68/91). Specificity of plasma NGS in those who were driver-negative by tissue NGS was 100% (19/19). In 17 patients with tumor tissue deemed insufficient for genotyping, plasma NGS identified four KRAS mutations. In 23 EGFR mutant cases with acquired resistance to targeted therapy, plasma NGS detected potential resistance mechanisms, including EGFR T790M and C797S mutations and ERBB2 amplification. Conclusions: Ultra-deep plasma NGS with clonal hematopoiesis filtering resulted in de novo detection of targetable oncogenic drivers and resistance mechanisms in patients with NSCLC, including when tissue biopsy was inadequate for genotyping.

Figures

References Powered by Scopus

Detection of circulating tumor DNA in early- and late-stage human malignancies

3791Citations
N/AReaders
Get full text

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

2464Citations
N/AReaders
Get full text

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

1741Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Liquid biopsy enters the clinic — implementation issues and future challenges

761Citations
N/AReaders
Get full text

Liquid biopsy: current technology and clinical applications

375Citations
N/AReaders
Get full text

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

366Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Li, B. T., Janku, F., Jung, B., Hou, C., Madwani, K., Alden, R., … Oxnard, G. R. (2019). Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: Results from the actionable genome consortium. Annals of Oncology, 30(4), 597–603. https://doi.org/10.1093/annonc/mdz046

Readers over time

‘16‘19‘20‘21‘22‘23‘24‘25020406080

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 56

48%

Researcher 47

40%

Professor / Associate Prof. 9

8%

Lecturer / Post doc 5

4%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 48

42%

Medicine and Dentistry 41

36%

Agricultural and Biological Sciences 19

17%

Pharmacology, Toxicology and Pharmaceut... 6

5%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1
News Mentions: 8
Social Media
Shares, Likes & Comments: 3

Save time finding and organizing research with Mendeley

Sign up for free
0